The Medical Letter on Drugs and Therapeutics
Extended-Release Trazodone (Oleptro) for Depression
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved the marketing of an extended-release formulation of trazodone (Oleptro – Angelini Labopharm) for treatment of major depressive disorder in adults. Immediate-release trazodone has been available for treatment of depression for many years, but is used mostly in low doses for its sedating effects.1

MECHANISM OF ACTION — Trazodone is both an antagonist at serotonin 5HT2A and 5HT2C receptors and a selective serotonin reuptake inhibitor. Its hypnotic activity at low doses is thought to be due mostly to 5HT2A antagonism.2

PHARMACOKINETICS — Taken on an empty stomach, peak serum concentrations (Cmax) of extended-release trazodone are lower than those with 100 mg three times daily of immediate-release trazodone. Taking the extended-release formulation with a high-fat meal can increase Cmax by 86%. The median time to Cmax (Tmax) ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Extended-Release Trazodone (Oleptro) for Depression
Article code: 1351c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian